American BriVision (ABVC) Reports Completion Clinical Trial for Treatment of Adult ADHD.
American BriVision (ABVC) Reports Completion of ABV-1505 Phase II Part I Clinical Trial for Treatment of Adult ADHD.
Last patient last visit (LPLV) marked the...
2020 Biotech Portfolio Soars 55%, We’re Amazed. Next Up: The Coming Gold Rush.
1. Yep, We Are Absolutely Amazed At The Biotech Stock Review's 2020 Watch List Performance – Especially In The Light Of – Well Everything....
Adding American BriVision (ABVC) $3.30 to Stocks We Expect Double List. $7.00 Price Potential.
Adding to Our 2020 Biotech 5-Pack, 5 Stocks We Expect to Double in 2020
To Put It Mildly, We Are Absolutely Amazed With Our 2020,...
Where is Citius Pharma (CTXR) in the FDA Approval Process?
We have a number of subscribers asking for an update on the FDA approval process for Mino-Lok. In layman's term (assuming approval) the answer...
2020 Biotech Portfolio Soars 55%, We’re Amazed.
1. Yep, We Are Absolutely Amazed At The Biotech Stock Review’s 2020 Watch List Performance – Especially In The Light Of – Well Everything. Our...
Citius (CTXR) CEO Myron Holubiak Live on TV, 1:20 Today, June 30th.
VIDEO: Citius CEO Myron Holubiak to Appear on TD Ameritrade Network's The Watch List with Nicole Petallides
LIVE CHART
- Live on-air interview to feature Citius...
Citius Pharma (CTXR) On The Move.
One Of Our Top 5 Biotech Picks For 2020 Up 23% Yesterday, Indicating Up Another 24% This Morning. Inquiring Minds Want To Know!
Citius (a...
Immunomedics (IMMU) $33 | Raising Price Potential to $60. American BriVision (ABVC) $3.00 |...
We Are Raising the Price Potential of Immunomedics (IMMU) to $60, Highest on the Street, and Initiating Coverage on Another $3.00 Medical Start-Up American...
Update: Biotech 5 Pack. 5 Biotech Stocks, we Expected to Double in 2020.
No Doubles Yet, But They're Doing Rather Well, Considering Everything. Our Confidence Remains Unwavered. Best Performer up 63%.
IN ORDER OF SHARE PRICE..LOW TO HIGH
Mitesco...
Immunomedics (IMMU) up 100% Today or $2 Billion in Value.
Again as mentioned a few weeks ago, our bearish market opinion is related to large-caps and large-cap funds and ETF's. If you find a small company whose...
Latest article
Party Time at uniQure (QURE). $48 up 443%
No Bells, no Baskets. But Still not out of the Woods!
We’re Up 360% in Six Weeks. Replimune (REPL).
That's a Gain of $604 Million, and That Ain't Bad!
Six brokerage firms downgraded Replimune (REPL), around the same time we added it to...
GeoVax (GOVX) Conference Call and Transcript.
Excellent Presentation. You Can Listen for 40 Minutes, or Read it in About Ten, Halleluiah.
Guess what we'll choose to do?
We have no...
